메뉴 건너뛰기




Volumn 14, Issue 5-6, 2009, Pages 316-320

Tailor-made drug treatment for children. Creation of an infrastructure for data-sharing and population PK-PD modeling

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; SULFAFURAZOLE; TACROLIMUS; TRAMADOL;

EID: 61649112659     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.11.004     Document Type: Review
Times cited : (57)

References (39)
  • 1
    • 0141857724 scopus 로고    scopus 로고
    • Developmental pharmacology - drug disposition, action, and therapy in infants and children
    • Kearns G.L., et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349 (2003) 1157-1167
    • (2003) N. Engl. J. Med. , vol.349 , pp. 1157-1167
    • Kearns, G.L.1
  • 2
    • 0037350150 scopus 로고    scopus 로고
    • Research in children
    • Burns J.P. Research in children. Crit. Care Med. 31 3 Suppl. (2003) S131-136
    • (2003) Crit. Care Med. , vol.31 , Issue.3 SUPPL
    • Burns, J.P.1
  • 3
    • 4444351808 scopus 로고    scopus 로고
    • Clinical trials in children
    • Caldwell P.H., et al. Clinical trials in children. Lancet 364 (2004) 803-811
    • (2004) Lancet , vol.364 , pp. 803-811
    • Caldwell, P.H.1
  • 4
    • 61649109321 scopus 로고    scopus 로고
    • Challenges for drug studies in children: CYP3A phenotyping as example
    • [Epub ahead of print]
    • de Wildt S.N., et al. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov. Today (2008) [Epub ahead of print]
    • (2008) Drug Discov. Today
    • de Wildt, S.N.1
  • 5
    • 0036020410 scopus 로고    scopus 로고
    • Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands
    • t Jong G.W., et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur. J. Clin. Pharmacol. 58 (2002) 293-297
    • (2002) Eur. J. Clin. Pharmacol. , vol.58 , pp. 293-297
    • t Jong, G.W.1
  • 6
    • 20244368931 scopus 로고    scopus 로고
    • Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children
    • Conroy S., et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320 (2000) 79-82
    • (2000) BMJ , vol.320 , pp. 79-82
    • Conroy, S.1
  • 7
    • 0034642054 scopus 로고    scopus 로고
    • Unapproved and off-label use of drugs in a children's hospital
    • t Jong G.W., et al. Unapproved and off-label use of drugs in a children's hospital. N. Engl. J. Med. 343 (2000) 1125
    • (2000) N. Engl. J. Med. , vol.343 , pp. 1125
    • t Jong, G.W.1
  • 8
    • 80051823470 scopus 로고
    • Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol
    • Sutherland J.M. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J. Dis. Child. 97 (1959) 761-767
    • (1959) AMA J. Dis. Child. , vol.97 , pp. 761-767
    • Sutherland, J.M.1
  • 9
    • 0021725723 scopus 로고
    • E-ferol: what happened and what now?
    • Phelps D.L. E-ferol: what happened and what now?. Pediatrics 74 (1984) 1114-1116
    • (1984) Pediatrics , vol.74 , pp. 1114-1116
    • Phelps, D.L.1
  • 10
    • 0000022275 scopus 로고
    • A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens
    • Andersen D.H., et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18 (1956) 614-625
    • (1956) Pediatrics , vol.18 , pp. 614-625
    • Andersen, D.H.1
  • 11
    • 0030890279 scopus 로고    scopus 로고
    • Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm
    • Breimer D.D., and Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm. Clin. Pharmacokinet. 32 (1997) 259-267
    • (1997) Clin. Pharmacokinet. , vol.32 , pp. 259-267
    • Breimer, D.D.1    Danhof, M.2
  • 12
    • 0033382294 scopus 로고    scopus 로고
    • Cytochrome P450 3A: ontogeny and drug disposition
    • de Wildt S.N., et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37 (1999) 485-505
    • (1999) Clin. Pharmacokinet. , vol.37 , pp. 485-505
    • de Wildt, S.N.1
  • 13
    • 0028869017 scopus 로고
    • Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin
    • van den Anker J.N., et al. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br. J. Clin. Pharmacol. 40 (1995) 439-443
    • (1995) Br. J. Clin. Pharmacol. , vol.40 , pp. 439-443
    • van den Anker, J.N.1
  • 14
    • 0035699615 scopus 로고    scopus 로고
    • Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children
    • Leeder J.S. Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr. Ther. Res. 62 (2001) 900-912
    • (2001) Curr. Ther. Res. , vol.62 , pp. 900-912
    • Leeder, J.S.1
  • 15
    • 42049113033 scopus 로고    scopus 로고
    • Pediatric antihypertensive trial failures: analysis of end points and dose range
    • Benjamin Jr. D.K., et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 51 (2008) 834-840
    • (2008) Hypertension , vol.51 , pp. 834-840
    • Benjamin Jr., D.K.1
  • 16
    • 0032494103 scopus 로고    scopus 로고
    • Impact of pharmacodynamic variability on drug delivery
    • Levy G. Impact of pharmacodynamic variability on drug delivery. Adv. Drug Deliv. Rev. 33 (1998) 201-206
    • (1998) Adv. Drug Deliv. Rev. , vol.33 , pp. 201-206
    • Levy, G.1
  • 17
    • 34548203082 scopus 로고    scopus 로고
    • Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations
    • Krekels E.H., et al. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin. Pharmacother. 8 (2007) 1787-1799
    • (2007) Expert Opin. Pharmacother. , vol.8 , pp. 1787-1799
    • Krekels, E.H.1
  • 18
    • 41949118720 scopus 로고    scopus 로고
    • Covariates of tramadol disposition in the first months of life
    • Allegaert K., et al. Covariates of tramadol disposition in the first months of life. Br. J. Anaesth. 100 (2008) 525-532
    • (2008) Br. J. Anaesth. , vol.100 , pp. 525-532
    • Allegaert, K.1
  • 19
    • 47949109211 scopus 로고    scopus 로고
    • Developmental changes in human liver CYP2D6 expression
    • Stevens J.C., et al. Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36 (2008) 1587-1593
    • (2008) Drug Metab. Dispos. , vol.36 , pp. 1587-1593
    • Stevens, J.C.1
  • 20
    • 49949152544 scopus 로고    scopus 로고
    • Using ontogeny information to build predictive models for drug elimination
    • Alcorn J., and McNamara P.J. Using ontogeny information to build predictive models for drug elimination. Drug Discov. Today 13 (2008) 507-512
    • (2008) Drug Discov. Today , vol.13 , pp. 507-512
    • Alcorn, J.1    McNamara, P.J.2
  • 21
    • 46149121257 scopus 로고    scopus 로고
    • Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants
    • Yang Z., and Wang S. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. J. Immunol. Methods 336 (2008) 98-103
    • (2008) J. Immunol. Methods , vol.336 , pp. 98-103
    • Yang, Z.1    Wang, S.2
  • 22
    • 0035021127 scopus 로고    scopus 로고
    • Use of saliva in therapeutic drug monitoring of caffeine in preterm infants
    • de Wildt S.N., et al. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. Ther. Drug Monit. 23 (2001) 250-254
    • (2001) Ther. Drug Monit. , vol.23 , pp. 250-254
    • de Wildt, S.N.1
  • 23
    • 0032832768 scopus 로고    scopus 로고
    • The use of the dried blood spot sample in epidemiological studies
    • Parker S.P., and Cubitt W.D. The use of the dried blood spot sample in epidemiological studies. J. Clin. Pathol. 52 (1999) 633-639
    • (1999) J. Clin. Pathol. , vol.52 , pp. 633-639
    • Parker, S.P.1    Cubitt, W.D.2
  • 24
    • 0031594230 scopus 로고    scopus 로고
    • Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test
    • Parker A.C., et al. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br. J. Clin. Pharmacol. 45 (1998) 176-178
    • (1998) Br. J. Clin. Pharmacol. , vol.45 , pp. 176-178
    • Parker, A.C.1
  • 25
    • 0003747347 scopus 로고    scopus 로고
    • Division of Clinical Pharmacology, University of California at San Francisco
    • Boeckmann A.J., et al. NONMEM User's Guide (1998), Division of Clinical Pharmacology, University of California at San Francisco
    • (1998) NONMEM User's Guide
    • Boeckmann, A.J.1
  • 26
    • 20644445856 scopus 로고    scopus 로고
    • Modelling approaches to dose estimation in children
    • Johnson T.N. Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol. 59 (2005) 663-669
    • (2005) Br. J. Clin. Pharmacol. , vol.59 , pp. 663-669
    • Johnson, T.N.1
  • 27
    • 34247173459 scopus 로고    scopus 로고
    • Population pharmacokinetic model for gatifloxacin in pediatric patients
    • Rubino C.M., et al. Population pharmacokinetic model for gatifloxacin in pediatric patients. Antimicrob. Agents Chemother. 51 (2007) 1246-1252
    • (2007) Antimicrob. Agents Chemother. , vol.51 , pp. 1246-1252
    • Rubino, C.M.1
  • 28
    • 14744276100 scopus 로고    scopus 로고
    • Pharmacokinetics of gatifloxacin in infants and children
    • Capparelli E.V., et al. Pharmacokinetics of gatifloxacin in infants and children. Antimicrob. Agents Chemother. 49 (2005) 1106-1112
    • (2005) Antimicrob. Agents Chemother. , vol.49 , pp. 1106-1112
    • Capparelli, E.V.1
  • 29
    • 33751335379 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery
    • Peeters M.Y., et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology 105 (2006) 1135-1146
    • (2006) Anesthesiology , vol.105 , pp. 1135-1146
    • Peeters, M.Y.1
  • 30
    • 33645511875 scopus 로고    scopus 로고
    • Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery
    • Peeters M.Y., et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 104 (2006) 466-474
    • (2006) Anesthesiology , vol.104 , pp. 466-474
    • Peeters, M.Y.1
  • 31
    • 0029550482 scopus 로고
    • Three new residual error models for population PK/PD analyses
    • Karlsson M.O., et al. Three new residual error models for population PK/PD analyses. J. Pharmacokinet. Biopharm. 23 (1995) 651-672
    • (1995) J. Pharmacokinet. Biopharm. , vol.23 , pp. 651-672
    • Karlsson, M.O.1
  • 32
    • 0027049043 scopus 로고
    • Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects
    • Mandema J.W., et al. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20 (1992) 511-528
    • (1992) J. Pharmacokinet. Biopharm. , vol.20 , pp. 511-528
    • Mandema, J.W.1
  • 33
    • 40549143738 scopus 로고    scopus 로고
    • Facilitation of drug evaluation in children by population methods and modelling
    • Tod M., et al. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47 (2008) 231-243
    • (2008) Clin. Pharmacokinet. , vol.47 , pp. 231-243
    • Tod, M.1
  • 34
    • 33750581706 scopus 로고    scopus 로고
    • Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide
    • Brendel K., et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm. Res. 23 (2006) 2036-2049
    • (2006) Pharm. Res. , vol.23 , pp. 2036-2049
    • Brendel, K.1
  • 35
    • 0033574245 scopus 로고    scopus 로고
    • Assessing the generalizability of prognostic information
    • Justice A.C., et al. Assessing the generalizability of prognostic information. Ann. Intern. Med. 130 (1999) 515-524
    • (1999) Ann. Intern. Med. , vol.130 , pp. 515-524
    • Justice, A.C.1
  • 36
    • 0034608969 scopus 로고    scopus 로고
    • Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group
    • McGinn T.G., et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 284 (2000) 79-84
    • (2000) JAMA , vol.284 , pp. 79-84
    • McGinn, T.G.1
  • 37
    • 0002322365 scopus 로고    scopus 로고
    • Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
    • Jonsson E.N., and Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58 (1999) 51-64
    • (1999) Comput. Methods Programs Biomed. , vol.58 , pp. 51-64
    • Jonsson, E.N.1    Karlsson, M.O.2
  • 38
    • 33847028671 scopus 로고    scopus 로고
    • Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis
    • Danhof M., et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 357-400
    • (2007) Annu. Rev. Pharmacol. Toxicol. , vol.47 , pp. 357-400
    • Danhof, M.1
  • 39
    • 0020324807 scopus 로고
    • Comparative pharmacokinetics of ceftazidime and moxalactam
    • Tjandramaga T.B., et al. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob. Agents Chemother. 22 (1982) 237-241
    • (1982) Antimicrob. Agents Chemother. , vol.22 , pp. 237-241
    • Tjandramaga, T.B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.